9-(3-hydroxy-2-(phosphonomethoxy)propyl)guanine | 113852-36-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 9-(3-hydroxy-2-(phosphonomethoxy)propyl)guanine
• 英文别名: 9-(3-hydroxy-2-phosphonylmethoxypropyl)guanine；9-(3-Hydroxy-2-(Phosphonomethoxy)propyl)guanine；9-(3-Hydroxy-2-phosphonomethoxypropyl)guanine；[1-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid
• CAS: 113852-36-1
• 化学式: C₉H₁₄N₅O₆P
• 分子量: 319.214
• InChiKey: VXDNQJCXIVLMQW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.7
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  172
• 氢给体数：
  5
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  9-(2,3-dihydroxypropyl)guanine 、 bis-(monomethoxy)trityl diethyl phosphonate 、 tosyloxymethyl diethylphosphonate 、 2-N-(monomethoxytrityl)-9-((2-diethylphosphonomethoxy)-3-(monomethoxytrityloxy)propyl)guanine 、 三甲基溴硅烷 、 4-甲氧基三苯基氯甲烷 生成 9-(3-hydroxy-2-(phosphonomethoxy)propyl)guanine
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Novel phosphonic acid based prodrugs of PMEA and its analogues
  申请人：——

  公开号：US20030229225A1

  公开（公告）日：2003-12-11

  Prodrugs of Formula I, their uses, their intermediates, and their method of manufacture are described: 1 wherein: M and V are cis to one another and MPO 3 H 2 is a phosphonic acid selected from the group consisting of 9-(2-phosphonylmethoxyethyl)adenine, (R)-9-(2-phosphonylmethoxy propyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, 9-(2-phosphonylmethoxy ethyloxy)adenine, 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine, 9-(3-hydroxy-2-phosphonylmethoxypropyl)guanine, and (S)-9-(3-fluoro-2-phosphonyl methoxypropyl)adenine; V is selected from a group consisting of phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-furanyl, 3-furanyl, 2-thienyl, and 3-thienyl, all optionally substituted with 1-3 substituents selected from a group consisting of F, Cl, Br, C1-C3 alkyl, CF 3 and OR 6 ; R6 is selected from the group consisting of C1-C3 alkyl, and CF 3 ; and pharmaceutically acceptable salts thereof.

  公式I的前药、它们的用途、它们的中间体以及它们的制造方法被描述：其中：M和V相对于彼此是顺式的，MPO3H2是从以下组中选择的膦酸，包括9-(2-膦甲氧基乙基)腺嘌呤，(R)-9-(2-膦甲氧基丙基)腺嘌呤，9-(2-膦甲氧基乙基)鸟嘌呤，9-(2-膦甲氧基乙氧基)腺嘌呤，9-(2-膦甲氧基乙基)-2,6-二氨基嘌呤，(S)-1-(3-羟基-2-膦甲氧基丙基)胞嘧啶，(S)-9-(3-羟基-2-膦甲氧基丙基)腺嘌呤，9-(3-羟基-2-膦甲氧基丙基)鸟嘌呤，以及(S)-9-(3-氟-2-膦甲氧基丙基)腺嘌呤；V从以下组中选择，包括苯基，2-吡啶基，3-吡啶基，4-吡啶基，2-呋喃基，3-呋喃基，2-噻吩基和3-噻吩基，所有这些基可选地被1-3个来自F、Cl、Br、C1-C3烷基、CF3和OR6的基替代；R6从C1-C3烷基和CF3的组中选择；以及其药学上可接受的盐。
• [EN] ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS<br/>[FR] ANALOGUES DE NUCLEOTIDES ENANTIOMERES ANTIRETROVIRAUX
  申请人：INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC

  公开号：WO1994003467A2

  公开（公告）日：1994-02-17

  (EN) Resolved enantiomers of formulae (IA) and (IB) wherein B is a purine or pyrimidine base or aza and/or deaza analogs thereof are useful in antiviral pharmaceutical compositions to treat retroviral infections.(FR) Des énantiomères dédoublés des formules (IA) et (IB) où B est une base purique ou pyrimidique, ou bien des analogues aza et/ou désaza de ceux-ci sont utiles dans des compositions pharmaceutiques antivirales pour traiter des infections rétrovirales.

  (中文) 公式（IA）和（IB）的旋光异构体，其中B是嘌呤或嘧啶碱基或其氮杂环和/或去氮杂环衍生物，可用于抗病毒药物组合物中，用于治疗逆转录病毒感染。
• Formulations and methods for treating rhinosinusitis
  申请人：Chaudry Imtiaz

  公开号：US20050180925A1

  公开（公告）日：2005-08-18

  The invention involves methods and formulations for treating or preventing rhinosinusitis, including but not limited to, bacterial-induced, viral-induced and/or fungus-induced rhinosinusitis in mammals, and/or rhinosinusitis not induced by an infective agent, such as bacteria, fungus or virus. In one embodiment, the formulation of the present invention comprises an anti-inflammatory agent (e.g. fluticasone propionate) having a specific particle size distribution profile. The formulation may also comprise an antifungal agent, antibiotic or antiviral agent.

  本发明涉及治疗或预防哺乳动物鼻窦炎的方法和配方，包括但不限于细菌感染、病毒感染和/或真菌感染引起的鼻窦炎，以及非由感染因素引起的鼻窦炎，例如细菌、真菌或病毒。在一种实施例中，本发明的配方包括具有特定粒径分布特征的抗炎药物（例如丙酸氟替卡松）。该配方还可以包括抗真菌药物、抗生素或抗病毒药物。
• Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives
  申请人：INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC

  公开号：EP0269947A1

  公开（公告）日：1988-06-08

  series of compounds of Formula I are described which are useful in treating viral infections, their compositions and use. In Formula I B is a purine or pyrimidine base; alk1, alk2 and alk3 are cheical bonds or alkylene groups; Q is hydrogen or hydroxyl; and R1 -R4 are hydrogen or alkyl.

  描述了一系列可用于治疗病毒感染的式 I 化合物及其组合物和用途。 在式 I 中，B 是嘌呤或嘧啶碱；alk1、alk2 和 alk3 是螯键或亚烷基；Q 是氢或羟基；R1 -R4 是氢或烷基。
• Chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
  申请人：INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC

  公开号：EP0452935A1

  公开（公告）日：1991-10-23

  The present invention provides a chiral nucleotide analog having the Formula I which is substantially free of the (S)-isomer and pharmaceutically acceptable salts and solvates thereof, and their pharmaceutical compositions, which is useful in the treatment of viral infections, especially those caused by human immunodeficiency virus (HIV).

  本发明提供了一种具有式 I 的手性核苷酸类似物 的手性核苷酸类似物、其药学上可接受的盐和溶剂及其药物组合物，可用于治疗病毒感染，尤其是由人类免疫缺陷病毒（HIV）引起的病毒感染。